Management of borderline resectable pancreatic cancer. Surg Oncol Clin N Am 2010 Apr;19(2):359-70
Date
02/18/2010Pubmed ID
20159519DOI
10.1016/j.soc.2009.11.006Scopus ID
2-s2.0-75849147865 (requires institutional sign-in at Scopus site) 9 CitationsAbstract
Borderline resectable pancreatic cancer is an emerging stage of disease defined by computed tomogrpahy criteria, patient (Katz type B), or disease characteristics (Katz type C). These patients are particularly well suited to a surgery-last strategy with induction therapy consisting of chemotherapy (gemcitabine alone or in combination) followed by chemoradiation. With appropriate selection and preoperative planning, many patients with borderline resectable disease derive clinical benefit from multimodality therapy. The use of a standardized system for the staging of localized pancreatic cancer avoids indecision and allows for the optimal treatment of all patients guided by the extent of their disease. In this article, 2 case reports are presented, and the term borderline resectable pancreatic cancer is discussed. The advantages of neoadjuvant therapy and surgery are also discussed.
Author List
Lal A, Christians K, Evans DBAuthors
Kathleen K. Christians MD Professor in the Surgery department at Medical College of WisconsinDouglas B. Evans MD Chair, Professor in the Surgery department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
AdenocarcinomaAntineoplastic Combined Chemotherapy Protocols
Chemotherapy, Adjuvant
Cisplatin
Combined Modality Therapy
Deoxycytidine
Fluorouracil
Humans
Male
Middle Aged
Neoadjuvant Therapy
Pancreatic Neoplasms
Preoperative Care
Radiotherapy, Adjuvant
Tomography, X-Ray Computed
